Telix 1H 2022 Financial Results and Company Update Investor Call
Telix advises that it will release financial results for the half-year ending 30 June 2022 on Thursday 18 August 2022.
APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging
Telix today reports on regulatory progress for the Company’s core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress in the major market of China with its strategic partner Grand Pharmaceutical Group Limited (Grand Pharma).
BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging
Telix and BAMF Health use Illuccix® for the first time with uEXPLORER® total-body PET scanner for prostate cancer imaging
Activities Report and Appendix 4C for June 2022 Quarter
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June 2022.
ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
Telix Announces a Final Patient Dosed and Recruitment Completed into the Phase III Pivotal ZIRCON Study of TLX250-CDx for Kidney Cancer Imaging
Kevin Richardson Appointed as CEO, Telix Americas
Telix announces that Kevin Richardson will commence in the role of CEO, Telix Americas, on 11 July 2022
Take a PSMA journey with Telix at EAU22
As a specialist in urology, Telix is delighted to invite you onboard the PSMA train. Our symposium, taking place during the EAU Congress 2022, will be an opportunity to ensure your PSMA knowledge is right on track. It’s an exciting field, and the train is moving fast, so join our expert travelers as they take you on a journey towards the latest developments in prostate cancer imaging and treatment.
Presentation to Jefferies Global Healthcare Conference
Telix is pleased to present a webcast of CEO and MD Dr. Christian Behrenbruch presenting at the Jefferies Global Healthcare Conference in New York City on Friday 10 June.
Telix at Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
Telix is sponsoring a symposium and presenting the company’s prostate cancer imaging agent and clinical programs at #SNMMI22, being held in Vancouver, Canada from 11-14 June, 2022.
Chief Medical Officer, Dr. Colin Hayward, Discussion with Wilsons Advisory
Telix Chief Medical Officer, Dr. Colin Hayward, was hosted this week by Shane Storey, Senior Research Analyst at Wilsons Advisory and Stockbroking Limited, to discuss R&D insights across Telix’s imaging and therapeutic research pipeline.